Prevalence and Correlates of Probable Nonalcoholic Steatohepatitis (NASH) in Pars Cohort Study

Overview

Journal Arch Iran Med

Specialty General Medicine

Date 2024 Nov 13

PMID 39534993

Authors

Amin Nakhostin-Ansari

Iman Menbari Oskouie

Reyhaneh Aghajani

Mohammad Mehdi Khadembashiri

Mohammad Ahmadi

Abdollah Gandomkar

Fatemeh Malekzadeh

Hossein Poustchi

Mohammad Reza Fattahi

Amir Anushiravani

Reza Malekzadeh

Affiliations

Soon will be listed here.

Abstract

Background: Studies on the prevalence of nonalcoholic steatohepatitis (NASH) and the factors associated with its high prevalence among Iranian people are limited. This study evaluated the prevalence of NASH and its associated factors among Iranian adults using Pars Cohort Study (PCS) data.

Methods: This cross-sectional study was conducted based on PCS, which includes 40-75-year-old adults from the Valashahr area. NASH was defined as alanine aminotransferase (ALT) higher than 40 U/L without evidence of hepatitis B or C infections. The prevalence of NASH and its associations with basic and demographic characteristics, socioeconomic characteristics, medical history, gastrointestinal symptoms, and laboratory tests were evaluated.

Results: Overall, 8734 patients, including 3917 men (44.8%), were enrolled in this study. The mean age of participants was 52.62 years (SD=9.68), and 605 individuals had NASH (6.9%). In the regression analysis, in contrast to female gender (OR=0.31, 95% CI=0.249‒0.386, <0.001) and age (OR=0.951, 95% CI=0.941‒0.962, <0.001), history of heart disease (OR=1.499, 95% CI=1.146‒1.962, =0.003), history of diabetes (OR=1.523, 95% CI=1.162‒1.995, =0.002), hypertension (OR=1.241, 95% CI=1.023‒1.506, =0.029), being overweight or obese (OR=2.192, 95% CI=1.755‒2.737, <0.001), being in the richest or second richest wealth index quantiles (OR=1.315, 95% CI=1.107‒1.156, =0.002), and increased waist circumference (OR=1.409, 95% CI=1.107‒1.793, <0.005) were independently associated with a higher risk of having NASH.

Conclusion: In this study, we determined the prevalence of NASH and found male gender, younger age, history of heart disease, history of diabetes, hypertension, socioeconomic status, and obesity as possible factors associated with a higher risk of NASH among Iranians.

References

Taylor A, Saunders M, Shingle D, Cimbala J, Zhou Z, Donahue H . Mechanically stimulated osteocytes regulate osteoblastic activity via gap junctions. Am J Physiol Cell Physiol. 2006; 292(1):C545-52. DOI: 10.1152/ajpcell.00611.2005. View

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M . Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50(8):1844-50. DOI: 10.2337/diabetes.50.8.1844. View

Gandomkar A, Poustchi H, Moini M, Moghadami M, Imanieh H, Fattahi M . Pars cohort study of non-communicable diseases in Iran: protocol and preliminary results. Int J Public Health. 2016; 62(3):397-406. DOI: 10.1007/s00038-016-0848-2. View

Carr R, Oranu A, Khungar V . Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am. 2016; 45(4):639-652. PMC: 5127277. DOI: 10.1016/j.gtc.2016.07.003. View

Boza C, Riquelme A, Ibanez L, Duarte I, Norero E, Viviani P . Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005; 15(8):1148-53. DOI: 10.1381/0960892055002347. View

Halon A, Patrzalek D, Rabczynski J . Hepatic steatosis in liver transplant donors: rare phenomenon or common feature of donor population?. Transplant Proc. 2006; 38(1):193-5. DOI: 10.1016/j.transproceed.2005.11.088. View

Rahmani A, Sayehmiri K, Asadollahi K, Sarokhani D, Islami F, Sarokhani M . Investigation of the Prevalence of Obesity in Iran: a Systematic Review and Meta-Analysis Study. Acta Med Iran. 2015; 53(10):596-607. View

Sayiner M, Koenig A, Henry L, Younossi Z . Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016; 20(2):205-14. DOI: 10.1016/j.cld.2015.10.001. View

10.

Giammarino A, Qiu H, Bulsara K, Khan S, Jiang Y, Da B . Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis. Hepatol Commun. 2021; 6(3):550-560. PMC: 8870017. DOI: 10.1002/hep4.1831. View

11.

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

12.

Roeb E, Geier A . Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Z Gastroenterol. 2019; 57(4):508-517. DOI: 10.1055/a-0784-8827. View

13.

Tran T, Changsri C, Shackleton C, Poordad F, Nissen N, Colquhoun S . Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol. 2006; 21(2):381-3. DOI: 10.1111/j.1440-1746.2005.03968.x. View

14.

Yatsuji S, Hashimoto E, Tobari M, Tokushige K, Shiratori K . Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. Hepatol Res. 2007; 37(12):1034-43. DOI: 10.1111/j.1872-034X.2007.00156.x. View

15.

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

16.

Yamamoto K, Takada Y, Fujimoto Y, Haga H, Oike F, Kobayashi N . Nonalcoholic steatohepatitis in donors for living donor liver transplantation. Transplantation. 2007; 83(3):257-62. DOI: 10.1097/01.tp.0000250671.06456.3f. View

17.

Lee C, Kim J, Jung Y . Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells. 2019; 8(10). PMC: 6835656. DOI: 10.3390/cells8101259. View

18.

Harnois F, Msika S, Sabate J, Mechler C, Jouet P, Barge J . Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2006; 16(2):183-8. DOI: 10.1381/096089206775565122. View

19.

Ledeboer M, Masclee A, Biemond I, Lamers C . Effect of medium- and long-chain triglycerides on lower esophageal sphincter pressure: role of CCK. Am J Physiol. 1998; 274(6):G1160-5. DOI: 10.1152/ajpgi.1998.274.6.G1160. View

20.

Ghassemi H, Harrison G, Mohammad K . An accelerated nutrition transition in Iran. Public Health Nutr. 2002; 5(1A):149-55. DOI: 10.1079/PHN2001287. View